| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS INCORPORATED | 1,229,512 | 47,262,000 | 35.06% | ||
| 2 | PARATEK PHARMACEUTICALS INC | 2,600,410 | 36,172,000 | 26.83% | ||
| 3 | Egalet Corp | 2,889,926 | 14,334,000 | 10.63% | ||
| 4 | FIBROGEN INC COM | 822,175 | 13,492,000 | 10.01% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 8,594,000 | 6.38% | ||
| 6 | ESSA Pharma | 1,696,969 | 5,006,000 | 3.71% | ||
| 7 | Pieris Pharmaceuticals | 2,262,832 | 3,643,000 | 2.70% | ||
| 8 | EDITAS MEDICINE INCORPORATED | 105,008 | 2,562,000 | 1.90% | ||
| 9 | Proteon Therapeutics | 250,000 | 2,008,000 | 1.49% | ||
| 10 | CymaBay Therapeutics | 606,100 | 1,055,000 | 0.78% | ||
| 11 | Dicerna Pharmaceuticals | 223,457 | 670,000 | 0.50% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-018706, filed 2016.08.03).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
